Seasonal influenza virus vaccine - Shire

Drug Profile

Seasonal influenza virus vaccine - Shire

Alternative Names: Preflucel; Vero cell-derived trivalent seasonal influenza vaccine - Shire

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Baxter International
  • Developer Baxalta; Shire
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 01 Apr 2015 No recent reports of development identified - Phase-III for Influenza virus infections (Prevention) in USA (IM)
  • 31 Mar 2013 Baxter completes a phase III trial for Influenza virus infections (prevention) in USA (NCT01773928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top